Text in the AI-gen images still needs some work, but quality and variety are impressiveRead more...
Infochimps raised $1.2M; SB Nation raised $10.5M; Novatel Wireless buys Enfora; Amazon buys Quidsi
Infochimps raised $1.2 million in its first round of funding. The Austin-based company has developed a marketplace for lists and other data sets. The round was led by DFJ Mercury.
SB Nation, which is a Washington, D.C.-based sports blog and news startup site, has raised $10.5 million, in its Series C round of funding. The round was led by Khosla Ventures. This is added to the roughly $13 million raised in prior rounds.
Amazon.com is buying household-goods retailer, Quidsi, the parent of Diapers.com, today for $540 million. The company was recently valued at $300 million.
Novatel Wireless is buying Enfora. Enfora provided wireless asset-management solutions. The buy out will be for about $64.5 million in cash.
HP released a new line of digital signage, aimed at a more budget conscious business today. The two devices, HP SignagePlayer mp8000s and HP SignagePlayer mp8000r, will come with an array of basic templates as well. The units will run $1,119 for the HP SignagePlayer mp8000s and $1,079 for the HP SignagePlayer mp8000r.
The U.S. wireless-data market grew 25% in the third quarter of 2010 According to Chetan Sharma. Sharma is a wireless-data industry analyst. The comparisons were made with the third quarter of 2009. When compared to the second quarter of 2010 the wireless-data market gained seven %. The industry, in total, is worth about $14 billion.
Monster.com and The White House, are teaming up this week to calm unemployment fears. People will be able to go to Monster’s Facebook Page, and ask the Obama Administration questions about the state of American’s employment. The event will last between November 8, and Sunday, November 14.
Support VatorNews by Donating
Read more from our "Trends and news" series
Streamline your marketing campaigns, client communication, project management - with AI assistanceRead more...
The San Francisco company readies to reveal its first clinical study results in the near termRead more...